Phase 3 N=956 Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema
Diabetic Macular Edema
Primary: Visual Acuity — 18.9; 28.7; 27.8 percentage of subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,101 A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Psoriasis
Primary: Percentage of Participants With a Physician's Global Assessment (PGA) Response of "Clear" or "Almost Clear" at Week 12 — 47.11; 68.18; 66.27; 14.95 percentage of…
Phase 3 N=1,000 Multicenter Study to Rule Out Myocardial Infarction by Cardiac Computed Tomography
Acute Coronary Syndrome · Myocardial Infarction · Unstable Angina Pectoris
Primary: Length of Hospital Stay — 23.2; 30.8 hours
Phase 3 N=626 Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
Iron Deficiency Anaemia · Chronic Kidney Disease
Primary: Kaplan-Meier Survival Analysis for Time to Other Anemia Therapy or Hb Trigger — 36; 49; 98; 117 participants — p=0.026
Phase 3 N=496 A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine
Tumor · Pain
Primary: Number of Participants Scored as Responder in Maintenance Phase. — 65; 75; 55 participants
Phase 3 N=921 A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Hormone Refractory Prostate Cancer · Bone Metastases
Primary: Overall Survival — 14.9; 11.3 Months — p=0.00005
Phase 3 N=42 Fish Oil Study for High Triglyceride Levels in Children
Hypertriglyceridemia
Primary: Change in Triglyceride Level — -52; -16 mg/dL
Phase 3 N=652 Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
Coronary Artery Disease (CAD) · Coronary Atherosclerosis
Primary: Change From Baseline in Percent Atheroma Volume(PAV) After 104 Weeks of Treatment — -0.33; 0.11 percentage of baseline
Phase 3 N=249 Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures
Epilepsy
Primary: Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. — 39.5; 21.65 Percent…
Phase 3 N=440 Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery
Pain · Inflammation · Cataract
Primary: Ocular Inflammation — 108; 53 eyes
Phase 3 N=6,100 Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age
Influenza Disease
Primary: Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of Geometric Mean Titers (GMTs) Against Homologous Strains — 28; 24; 27; 1537 Titers
Phase 3 N=1,186 Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone
Metastatic Colorectal Cancer
Primary: Progression-free Survival (PFS) — 5.9; 3.9; 5.0; 4.9 months — p=0.0036
Phase 3 N=846 A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).
Perennial Allergic Rhinitis · PAR
Primary: The Change From Baseline in Average Daily Subject-reported AM and PM Reflective Total Nasal Symptom Scores (rTNSS) Averaged Weekly Over the First 6 Weeks of the…
Phase 3 N=583 Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer (NSCLC)
Primary: Overall Survival (OS) Time — 16.1; 15.5 months
Phase 3 N=15 Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans
Hyperlipidemia
Primary: Apolipoprotein B48 Production Rate After Acute Oral Administration of 100mg Sitagliptin (Compared to Placebo) — 122.9; 60.6 ug/kg/day